Rituximab in Patients With ST-elevation Myocardial Infarction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 372 participants.

Also called NCT05211401

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 372 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05211401
  • EudraCT 2021-003340-24
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05211401. Randomized; double masking; primary purpose treatment. Start 2022-06-01 (actual); primary completion 2027-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rituximab in Patients With ST-elevation Myocardial Infarction
Acronym
RITA-MI2
Condition
ST Elevated Myocardial Infarction
Intervention (Drug)
Active arm 1000 mg
Intervention (Drug)
Placebo arm
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Institut National de la Santé Et de la Recherche Médicale, France (class: other government)

Record details

Record id
cardio:ct-nct05211401
Content hash
639e6f38367d6e6445b3e97b1c87adde143283635a614393c3b75cfadb751601